Trial timing slips, but a new sepsis designation adds momentum.
ICU SeaStar Medical Holding Corporation
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ICU
—
—
What changed
Recent filings, trades and movesKey stats
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 17
- List Date
- 2022-10-31
- CIK
- 0001831868
- Last Earnings
- Aug 12
- Headquarters
- Denver, CO
- Homepage
- https://www.seastarmedical.com
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 4.37% | 72.96% | 14.87% | -9.54% | 20.66% |
| Feb | -- | -21.64% | -11.59% | -24.12% | 9.52% | -11.96% |
| Mar | -- | -38.82% | -7.08% | -6.21% | 37.27% | -3.71% |
| Apr | -- | 22.16% | -39.89% | -14.00% | 16.29% | -3.86% |
| May | -- | -75.87% | -20.21% | -8.46% | -15.10% | -29.91% |
| Jun | -- | -5.39% | -15.67% | -63.92% | 0.82% | -21.04% |
| Jul | -- | 0.21% | -5.78% | 25.47% | -35.20% | -3.83% |
| Aug | -- | -49.53% | -40.46% | 39.82% | -2.03% | -13.05% |
| Sep | -- | 5.39% | -12.88% | -37.75% | 31.77% | -3.37% |
| Oct | 0.00% | 96.81% | -24.21% | -8.65% | -40.27% | 4.74% |
| Nov | -49.76% | -42.58% | -17.49% | -43.52% | -61.72%* | -43.01% |
| Dec | -16.33% | -18.59% | -18.49% | -23.57% | -- | -19.24% |
| Total | -57.96% | -93.16% | -85.68% | -90.00% | -74.11% | -80.18% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.21
SMA 50: $2.93
SMA 200: $3.29
Current: $0.82
EMA 12: $1.80
EMA 26: $2.29
MACD: -0.4879 | Signal: -0.1076
BEARISH
ADX (14): 24.84
WEAK TREND
+DI: 10.42
−DI: 42.45
Momentum Oscillators
RSI (14): 20.67
OVERSOLD
Stoch %K: 3.97
Stoch %D: 5.05
Williams %R: -99.27
Volume & Volatility
BB Upper: $3.39
BB Lower: $1.04
OVERSOLD
OBV: 27,950,027
Vol SMA 20: 284,047
Vol ROC: 618.44%
ATR: $0.31
True Range: $0.27
HV 20: 234.9%
HV 30: 219.7%
HV 60: 175.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-14T00:00:00 – 2026-11-12T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All ICU news →
ICU Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Put vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put
—
—
pts
EXTREME
ATM — / Put —
30 DTE / 10d put
—
—
pts
EXTREME
ATM — / Put —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.4114
Alpha: -111.18%
Correlation: 0.1579
R-Squared: 2.5%
Stock Volatility: 121.9%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
ICU Institutional Ownership (13F)
Filings for 2026-06-30 · 8 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ICU Insider Trading (Form 4)
Latest: 2026-08-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Michael Messinger | Chief Financial Officer | Buy (P) | +750 | $3.27 | $2.5K | EDGAR |
| 2026-07-02 | Jennifer A Baird | Director | Award (A) | +4,000 | — | EDGAR | |
| 2026-07-02 | John Neuman | Director | Award (A) | +4,000 | — | EDGAR | |
| 2026-07-02 | Kevin Chung | Chief Medical Officer | Award (A) | +7,202 | — | EDGAR | |
| 2026-07-02 | Kenneth Van Heel | Director | Award (A) | +4,000 | — | EDGAR | |
| 2026-07-02 | Eric Schlorff | Chief Executive Officer | Award (A) | +10,288 | — | EDGAR | |
| 2026-07-02 | Bernadette N Vincent | Director | Award (A) | +4,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ICU Insider Holdings
7 insiders · @ $0.82
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Eric Schlorff | Chief Executive Officer | 50,140 | $41.0K | $0 | 1 | 2026-07-02 |
| 2 | Kevin Chung | Chief Medical Officer | 28,021 | $22.9K | $0 | 1 | 2026-07-02 |
| 3 | John Neuman | Director | 16,200 | $13.3K | $0 | 1 | 2026-07-02 |
| 4 | Kenneth Van Heel | Director | 11,940 | $9.8K | $0 | 1 | 2026-07-02 |
| 5 | Jennifer A Baird | Director | 10,620 | $8.7K | $0 | 1 | 2026-07-02 |
| 6 | Bernadette N Vincent | Director | 8,200 | $6.7K | $0 | 1 | 2026-07-02 |
| 7 | Michael Messinger | Chief Financial Officer | 2,500 | $2.0K | $2.5K | 1 | 2026-08-19 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ICU Board & Officers
As of SEC filings through Aug 19, 2026Directors 4
- Kenneth Van Heel · since Oct 28, 2022
- Bernadette N Vincent · since Jun 4, 2024
- Jennifer A Baird · since Jun 4, 2024
- John Neuman · since Jun 5, 2024
Officers 4
- Eric Schlorff · Chief Executive Officer · since Oct 28, 2022
- Michael Messinger · Chief Financial Officer · since Nov 14, 2025
- Kevin Chung · Chief Medical Officer · since Oct 28, 2022
- Bradford K Towne · Principal Accounting Officer · since Aug 26, 2025
Changes in the last 10 years (29)
| Feb 10, 2026 | Eric Schlorff no longer listed as a director in SEC filings |
| Nov 14, 2025 | Michael Messinger became Chief Financial Officer |
| Aug 26, 2025 | Bradford K Towne became Principal Accounting Officer |
| Jun 5, 2024 | The company announced the departure of Andres Lobo from the board in an SEC filing |
| Jun 5, 2024 | John Neuman became a director |
| Jun 4, 2024 | Jennifer A Baird became a director |
| Jun 4, 2024 | Bernadette N Vincent became a director |
| Jan 10, 2024 | David A Green became Chief Financial Officer |
| Apr 10, 2023 | Richard D. Russell no longer listed as Chief Financial Officer in SEC filings |
| Apr 10, 2023 | Bruce M. Rodgers no longer listed as President and CEO in SEC filings |
| Oct 28, 2022 | Union Carbide Employees' Pension Plan Trust became a 10% owner |
| Oct 28, 2022 | Rick Barnett became a director |
| Oct 28, 2022 | Kevin Chung became Chief Medical Officer |
| Oct 28, 2022 | Kenneth Van Heel became a director |
| Oct 28, 2022 | Eric Schlorff became a director |
| Oct 28, 2022 | Eric Schlorff became Chief Executive Officer |
| Oct 28, 2022 | Dow Employees' Pension Plan Trust became a 10% owner |
| Oct 28, 2022 | Caryl Baron became Interim CFO |
| Oct 28, 2022 | Andres Lobo became a director |
| Oct 28, 2022 | Allan Collins became a director |
| Jan 25, 2021 | Richard D. Russell became a director |
| Jan 25, 2021 | Richard D. Russell became Chief Financial Officer |
| Jan 25, 2021 | Martin A Traber became a director |
| Jan 25, 2021 | Lm Funding America, Inc. became a 10% owner |
| Jan 25, 2021 | LMFAO Sponsor, LLC became a 10% owner |
| Jan 25, 2021 | Craig E Burson became a director |
| Jan 25, 2021 | Bruce M. Rodgers became a director |
| Jan 25, 2021 | Bruce M. Rodgers became President and CEO |
| Jan 25, 2021 | Bruce H Bennett became a director |
Not reported recently (13)
- David A Green · Last reported as Chief Financial Officer in an SEC filing dated Apr 3, 2025
- Rick Barnett · Last reported as a director in an SEC filing dated Nov 15, 2024
- Allan Collins · Last reported as a director in an SEC filing dated Nov 15, 2024
- Richard D. Russell · Last reported as a director in an SEC filing dated Apr 16, 2024
- Bruce M. Rodgers · Last reported as a director in an SEC filing dated Apr 16, 2024
- Caryl Baron · Last reported as Interim CFO in an SEC filing dated Nov 29, 2023
- Lm Funding America, Inc. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2022
- LMFAO Sponsor, LLC · Last reported as a 10% owner in an SEC filing dated Nov 1, 2022
- Union Carbide Employees' Pension Plan Trust · Last reported as a 10% owner in an SEC filing dated Nov 1, 2022
- Dow Employees' Pension Plan Trust · Last reported as a 10% owner in an SEC filing dated Nov 1, 2022
- Martin A Traber · Last reported as a director in an SEC filing dated Jan 26, 2021
- Bruce H Bennett · Last reported as a director in an SEC filing dated Jan 25, 2021
- Craig E Burson · Last reported as a director in an SEC filing dated Jan 25, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-12
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-12 | Earnings results | EDGAR |
| 2026-11-03 | Other events | EDGAR |
| 2026-10-05 | Material agreement · Unregistered share sale · Other events | EDGAR |
| 2026-08-12 | Earnings results | EDGAR |
| 2026-07-01 | Director or officer change | EDGAR |
| 2026-06-17 | Director or officer change · Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
3 ETFs hold ICU
3 shown · $142.99K total exposure
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
ICU vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| SYK Stryker Corporation | $118.9B | 32.9 | +7.9% | −11.3% | 28 |
| MMM 3M Company | $96.0B | 27.4 | +1.7% | +13.5% | 11 |
| BSX Boston Scientific Corp. | $64.1B | 18.8 | +8.9% | −53.2% | 13 |
| BDX Becton, Dickinson and Co. | $58.8B | 65.8 | +1.2% | +11.7% | 21 |
| MDLN Medline Inc. Class A common stock | $35.1B | 0.0 | — | −3.2% | 29 |
| RMD ResMed Inc. | $33.6B | 21.8 | +9.0% | −2.2% | 9 |
| DXCM DexCom, Inc. | $30.4B | 32.9 | +13.0% | +25.6% | 25 |
| WST West Pharmaceutical Services, Inc. | $28.7B | 46.8 | +12.6% | +50.8% | 12 |
| ICU SeaStar Medical Holding Corporation Comm | $6M | — | — | −68.9% | — |
| Peer median | $46.9B | 30.1 | +8.9% | +4.7% | 17 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.